Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Por um escritor misterioso
Descrição
Current Oncology, Free Full-Text
Pharmaceuticals, Free Full-Text
Neoadjuvant immunotherapy: Results in melanoma show promise and pave the way for other solid tumors
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA
Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy
Timing of pembrolizumab makes a difference in resectable melanoma
VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma
melanoma 2 Minute Medicine
Frontiers Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Neoadjuvant-Adjuvant Pembrolizumab Better Than Adjuvant-Only in Melanoma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
